GCIA
AUPH icon

Gabelli & Co Investment Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,000
Closed -$75K – 296
2022
Q3 		$75K Hold
10,000
– – 0.01% 346
2022
Q2 		$101K Hold
10,000
– – 0.01% 355
2022
Q1 		$124K Sell
10,000
-500
-5% -$7.73K 0.02% 371
2021
Q4 		$240K Buy
10,500
+500
+5% +$11.8K 0.03% 332
2021
Q3 		$221K Hold
10,000
– – 0.03% 337
2021
Q2 		$130K Hold
10,000
– – 0.02% 356
2021
Q1 		$130K Buy
+10,000
New +$145K 0.02% 359

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Gabelli & Co Investment Advisers's AUPH Position: Q4 2022 in Review

Gabelli & Co Investment Advisers sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2022, closing a stake of 10,000 shares — an estimated $75K sold.

Gabelli & Co Investment Advisers first reported a position in AUPH in Q1 2021 and held it in 7 quarters. The position peaked at $240K in Q4 2021. 192 funds tracked by Wall St. Rank hold AUPH as of Q4 2022.

  • Gabelli & Co Investment Advisers reported no remaining Aurinia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 10,000 Aurinia Pharmaceuticals shares in Q4 2022, an estimated $75K.
  • Gabelli & Co Investment Advisers first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Gabelli & Co Investment Advisers's Aurinia Pharmaceuticals position peaked at $240K in Q4 2021.
  • 192 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2022.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2022, filed 13 Feb 2023.